Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

No magic pill for treating dementia symptoms

02.02.2005


Many of the drugs commonly prescribed to treat agitation, delusions and other symptoms that can accompany dementia are not effective, researchers from Wake Forest University Baptist Medical Center and colleagues report this week in the Journal of the American Medical Association.



"Our review of 29 research studies found that drug therapies are not particularly effective for managing symptoms such as agitation, wandering and delusions that are observed in most patients with dementia at some point in the illness," said Kaycee Sink, M.D., lead researcher. "There is no clear standard of care, and treatment is often based on local prescribing customs."

While the primary symptoms of Alzheimer’s disease and other forms of dementia involve memory deficits, other symptoms, including agitation, aggression, delusions, hallucinations, repetitive vocalizations and wandering have been observed in 60 percent to 98 percent of patients. "Dementia-related behaviors are very distressing to both caregivers and medical professionals," said Sink, a geriatrician. "It was discouraging to find that we currently don’t have good drug therapies for them."


More than half of people over age 85 are affected by dementia. Dementia-related behavioral problems are associated with longer hospital stays and often lead to placement in a nursing home. About 30 percent of the cost of caring for patients with Alzheimer’s disease is attributed to managing these symptoms, Sink said.

Sink and colleagues, Karen F. Holden, M.D., and Kristine Yaffe, M.D., both from the University of California at San Francisco, reviewed 29 research studies published between 1966 and mid-2004 that involved drug therapy commonly used for patients with dementia-related behaviors.

The study was designed to evaluate the effectiveness of current treatments for these behaviors and provide physicians with an evidence-based assessment of treatment options. The researchers analyzed data from studies evaluating more than 15 drugs that are commonly prescribed for dementia symptoms, including antipsychotics, antidepressants and mood stabilizers. They found that two drugs (risperidone and olanzapine) in a class known as atypical antipsychotics have the best evidence for effectiveness. "However, the effects are modest and are complicated by an increased risk of stroke," the authors write. "Physicians considering prescribing these drugs should discuss the potential risks and benefits with patients and their caregivers."

Because federal expenditures for dementia are expected to triple in the next 10 years, the authors said it is essential to find more effective treatments. They said non-drug therapies should always be considered first, and that some small studies have shown that music therapy, aromatherapy, pet therapy and caregiver education may be effective. "Larger, well-designed controlled trials of non-drug interventions are needed," said Sink, an assistant professor of internal medicine – geriatrics.

The authors said that additional studies of drug therapy are also needed and that a large multi-center center study now under way to compare four atypical antipsychotic drugs will be particularly valuable.

Karen Richardson | EurekAlert!
Further information:
http://www.wfubmc.edu

More articles from Health and Medicine:

nachricht Team discovers how bacteria exploit a chink in the body's armor
20.01.2017 | University of Illinois at Urbana-Champaign

nachricht Rabies viruses reveal wiring in transparent brains
19.01.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

Helmholtz International Fellow Award for Sarah Amalia Teichmann

20.01.2017 | Awards Funding

An innovative high-performance material: biofibers made from green lacewing silk

20.01.2017 | Materials Sciences

Ion treatments for cardiac arrhythmia — Non-invasive alternative to catheter-based surgery

20.01.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>